Introduction: Mayo clinic classification (MCC) has been proposed in patients with autosomal dominant polycystic kidney disease (ADPKD) to identify who may experience a rapid decline of renal function. Our aim was to validate this predictive model in a population from southern Spain. Methods: ADPKD patients with measurements of height-adjusted total kidney volume (HtTKV) and baseline estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 were selected. Last eGFR was estimated with Mayo Clinic (MC) equation and bias and accuracy were studied. We also analyzed predictive capacity of MCC classes using survival analysis and Cox regression models. Results: We included 134 patients with a mean follow-up of 82 months. While baseline eGFR was not different between classes, last eGFR decreased significantly with them. eGFR variation rate was different according to the MCC class with a more rapid decline in 1C, 1D, and 1E classes. Final eGFR predicted was not significantly different from the real one, with an absolute bias of 0.6 ± 17.0 mL/min/1.73 m2. P10 accuracy was low ranging from 37.5 to 59.5% in classes 1C, 1D, and 1E. Using MC equation, the rate of eGFR decline was underestimated in 1C, 1D, and 1E classes. Cox regression analysis showed that MCC class is a predictor of renal survival after adjusting with baseline eGFR, age, sex, and HtTKV, with 1D and 1E classes having the worst prognosis. Conclusion: MCC classification is able to identify patients who will undergo a more rapid decline of renal function in a Spanish population. Prediction of future eGFR with MC equation is acceptable as a group, although it shows a loss of accuracy considering individual values. The rate of eGFR decline calculated using MC equation can underestimate the real rate presented by patients of 1C, 1D, and 1E classes.

1.
Franz
KA
,
Reubi
FC
.
Rate of functional deterioration in polycystic kidney disease
.
Kidney Int
.
1983
;
23
(
3
):
526
9
. .
2.
Fick-Brosnahan
GM
,
Belz
MM
,
McFann
KK
,
Johnson
AM
,
Schrier
RW
.
Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study
.
Am J Kidney Dis
.
2002
;
39
(
6
):
1127
34
. .
3.
Grantham
JJ
,
Mulamalla
S
,
Swenson-Fields
KI
.
Why kidneys fail in autosomal dominant polycystic kidney disease
.
Nat Rev Nephrol
.
2011
;
7
(
10
):
556
66
. .
4.
Grantham
JJ
,
Chapman
AB
,
Torres
VE
.
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes
.
Clin J Am Soc Nephrol
.
2006
;
1
(
1
):
148
57
. .
5.
Chapman
AB
,
Bost
JE
,
Torres
VE
,
Guay-Woodford
L
,
Bae
KT
,
Landsittel
D
,
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease
.
Clin J Am Soc Nephrol
.
2012
;
7
(
3
):
479
86
. .
6.
Grantham
JJ
,
Torres
VE
,
Chapman
AB
,
Guay-Woodford
LM
,
Bae
KT
,
King
BF
 Jr.
,
Volume progression in polycystic kidney disease
.
N Engl J Med
.
2006
;
354
(
20
):
2122
30
. .
7.
Grantham
JJ
,
Cook
LT
,
Torres
VE
,
Bost
JE
,
Chapman
AB
,
Harris
PC
,
Determinants of renal volume in autosomal-dominant polycystic kidney disease
.
Kidney Int
.
2008
;
73
:
108
16
. .
8.
King
BF
,
Reed
JE
,
Bergstralh
EJ
,
Sheedy
PF
 2nd
,
Torres
VE
.
Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease
.
J Am Soc Nephrol
.
2000
;
11
(
8
):
1505
11
. .
9.
Higashihara
E
,
Nutahara
K
,
Okegawa
T
,
Shishido
T
,
Tanbo
M
,
Kobayasi
K
,
Kidney volume and function in autosomal dominant polycystic kidney disease
.
Clin Exp Nephrol
.
2014
;
18
(
1
):
157
65
. .
10.
US Food and Drug Administration
.
Qualification of biomarker: total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease
. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458483.pdf. Accessed 2016 Dec 30.
11.
European Medicines Agency
.
Qualification opinion. Total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)
. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/WC500196569.pdf. Accessed 2016 Dec 30.
12.
Yu
ASL
,
Shen
C
,
Landsittel
DP
,
Harris
PC
,
Torres
VE
,
Mrug
M
,
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease
.
Kidney Int
.
2018
;
93
(
3
):
691
9
. .
13.
Irazabal
MV
,
Rangel
LJ
,
Bergstralh
EJ
,
Osborn
SL
,
Harmon
AJ
,
Sundsbak
JL
,
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials
.
J Am Soc Nephrol
.
2015 Jan
;
26
(
1
):
160
72
. .
14.
Irazabal
MV
,
Abebe
KZ
,
Bae
KT
,
Perrone
RD
,
Chapman
AB
,
Schrier
RW
,
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial
.
Nephrol Dial Transplant
.
2017
;
32
(
11
):
1857
65
. .
15.
Brosnahan
GM
,
Abebe
KZ
,
Moore
CG
,
Rahbari-Oskoui
FF
,
Bae
KT
,
Grantham
JJ
,
Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials
.
Am J Kidney Dis
.
2018
;
71
(
5
):
666
76
. .
16.
Irazabal
MV
,
Blais
JD
,
Perrone
RD
,
Gansevoort
RT
,
Chapman
AB
,
Devuyst
O
,
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial
.
Kidney Int Rep
.
2016
;
1
(
4
):
213
20
. .
17.
Chebib
FT
,
Perrone
RD
,
Chapman
AB
,
Dahl
NK
,
Harris
PC
,
Mrug
M
,
A practical guide for treatment of rapidly progressive ADPKD with tolvaptan
.
J Am Soc Nephrol
.
2018 Oct
;
29
(
10
):
2458
70
. .
18.
Müller
RU
,
Haas
CS
,
Sayer
JA
.
Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
.
Clin Kidney J
.
218
;
11
(
1
):
62
9
. .
19.
Edwards
ME
,
Chebib
FT
,
Irazabal
MV
,
Ofstie
TG
,
Bungum
LA
,
Metzger
AJ
,
Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease
.
Clin J Am Soc Nephrol
.
2018 Aug 7
;
13
(
8
):
1153
61
. .
20.
Chapman
AB
,
Guay-Woodford
LM
,
Grantham
JJ
,
Torres
VE
,
Bae
KT
,
Baumgarten
DA
,
Consortium for radiologic imaging studies of polycystic kidney disease cohort. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort
.
Kidney Int
.
2003 Sep
;
64
(
3
):
1035
45
.
21.
Yu
ASL
,
Shen
C
,
Landsittel
DP
,
Harris
PC
,
Torres
VE
,
Mrug
M
,
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease
.
Kidney Int
.
2018
;
93
:
691
9
. .
22.
Harris
PC
,
Bae
KT
,
Rossetti
S
,
Torres
VE
,
Grantham
JJ
,
Chapman
AB
,
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease
.
J Am Soc Nephrol
.
2006
;
17
:
3013
9
. .
23.
Yu
ASL
,
Shen
C
,
Landsittel
DP
,
Grantham
JJ
,
Cook
LT
,
Torres
VE
,
Consortium for radiologic imaging studies of polycystic kidney disease (CRISP). Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease
.
Kidney Int
.
2019
;
95
(
5
):
1253
61
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.